Federal Register / Vol. 66, No. 122 / Monday, June 25, 2001 / Notices 33715

Drug Schedule

Marihuana (7360) ......................... I

Tetrahydrocannabinols (7370) ..... I

Mescaline (7381) .......................... I

4-Bromo-2,5-

dimethoxyamphetamine (7391).

I

4-Bromo-2,5-

dimethoxyphenethylamine

(7392).

I

4-Methyl-2,5-

dimethoxyamphetamine (7395).

I

2,5-Dimethoxyamphetamine

(7396).

I

3,4-Methylenedioxyamphetamine

(7400).

I

3,4-Methylenedioxy-Nethylamphetamine (7404).I

3,4-

Methylenedioxymethamphetamine (7405).

I

4-Methoxyamphetamine (7411) ... I

Psilocybin (7437) .......................... I

Psilocyn (7438) ............................. I

Heroin (9200) ............................... I

Pholcodine (9314) ........................ I

Tilidine (9750) ............................... II

Amphetamine (1100) .................... II

Methamphetamine (1105) ............ II

Amobarbital (2125) ....................... II

Pentobarbital (2270) ..................... II

Cocaine (9041) ............................. II

Codeine (9050) ............................. II

Etorphine (9056) ........................... II

Dihydrocodeine (9120) ................. II

Oxycodone (9143) ........................ II

Hydromorphone (9150) ................ II

Benzoylecgonine (9180) ............... II

Ethylmorphine (9190) ................... II

Meperidine (9230) ........................ II

Methadone (9250) ........................ II

Dextropropoxyphene, bulk (nondosage forms) (9273).II

Morphine (9300) ........................... II

Thebaine (9333) ........................... II

Levo-alphacetylmethadol (9648) .. II

Oxymorphone (9652) ................... II

The firm plans to import small

quantities of the listed controlled

substances for the manufacture of

analytical reference standards.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Cerilliant Corporation to

import the above listed controlled

substances is consistent with the public

interest and with United States

obligations under international treaties,

conventions, or protocols in effect on

May 1, 1971, at this time. DEA has

investigated Cerilliant Corporation to

ensure that the company’s registration is

consistent with the public interest. This

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to Section 1008(a)

of the Controlled Substances Import and

Export Act and in accordance with Title

21, Code of Federal Regulations, Section

1301.34, the above firm is granted

registration as an importer of the basic

classes of controlled substances listed

above.

Dated: June 4, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–15836 Filed 6–22–01; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated November 20, 2000,

and published in the Federal Register

on November 5, 2000, (65 FR 75959),

Knoll Pharmaceutical Company, 30

North Jefferson Road, Whippany, New

Jersey 07981, made application by

renewal to the Drug Enforcement

Administration to be registered as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Dihydromorphine (9145) ............... I

Hydromorphone (9150) ................ II

The firm plans to produce bulk

product and finished dosage units for

distribution to its customers.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Knoll Pharmaceutical

Company to manufacture the listed

controlled substances is consistent with

the public interest at this time. DEA has

investigated Knoll Pharmaceutical

Company on a regular basis to ensure

that the company’s continued

registration is consistent with the public

interest. These investigations have

included inspection and testing of the

company’s physical security systems,

audits of the company’s records,

verification of the company’s

compliance with state and local laws,

and a review of the company’s

background and history. Therefore,

pursuant to 21 U.S.C. 823 and 28 CFR

0.100 and 0.104, the Deputy Assistant

Administrator, Office of Diversion

Control, hereby orders that the

application submitted by the above firm

for registration as a bulk manufacturer

of the basic classes of controlled

substances listed above is granted.

Dated: June 4, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 01–15834 Filed 6–22–01; 8:45 am]

BILLING CODE 4410–09–M

NATIONAL AERONAUTICS AND

SPACE ADMINISTRATION

[Notice (01–080)]

NASA Advisory Council (NAC), Space

Science Advisory Committee (SScAC),

Structure and Evolution of the

Universe Subcommittee

AGENCY: National Aeronautics and

Space Administration.

ACTION: Notice of Meeting.

SUMMARY: In accordance with the

Federal Advisory Committee Act, Pub.

L. 92–463, as amended, the National

Aeronautics and Space Administration

announces a meeting of the NASA

Advisory Council, Space Science

Advisory Committee, Structure and

Evolution of the Universe

Subcommittee.

DATES: Tuesday, July 10, 2001, 8:30 a.m.

to 5:30 p.m., and Wednesday, July 11,

2001, 8:30 a.m. to 5 p.m.

ADDRESS: National Aeronautics and

Space Administration, Conference

Room 7H46, 300 E Street, SW,

Washington, DC 20546.

FOR FURTHER INFORMATION CONTACT: Dr.

Alan Bunner, Code S, National

Aeronautics and Space Administration,

Washington, DC 20546, (202) 358–2150.

SUPPLEMENTARY INFORMATION: The

meeting will be open to the public up

to the capacity of the room. The agenda

for the meeting is as follows:

—Associate Administrator’s Program

Status Report

—Report on the Structure and Evolution

of the Universe Annual State of the

Theme

—Future of Structure and Evolution of

the Universe Subcommittee

Membership

—Status of Astro-E2

—Internationalization of future x-ray

missions

It is imperative that the meeting be

held on these dates to accommodate the

scheduling priorities of the key

participants. Visitors will be requested

to sign a visitors register.